Immunotherapy Trials Show Promise for Treating Canine Melanoma

by Anand Patadiya | Oct 2, 2024

Ankyra Therapeutics announces $45 Million Series B Financing and Appoints Howard L. Kaufman M.D. as Chief Medical Officer

by Anand Patadiya | Oct 2, 2024

BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the...

Ankyra Therapeutics Appoints Howard L. Kaufman, M.D. as President and Chief Executive Officer

by Anand Patadiya | Oct 2, 2024

Highly Accomplished Thought Leader with Proven Track Record of Immunotherapy Drug Development BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents, announced today that the Board...

Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute

by Anand Patadiya | Oct 2, 2024

BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has established a formal Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to pursue basic, translational and clinical research using Ankyra...

Ankyra Therapeutics Announces Research Collaboration with the College of Veterinary Medicine at the University of Illinois at Urbana-Champaign

by Anand Patadiya | Oct 2, 2024

BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has entered into a formal research collaboration with the College of Veterinary Medicine at the University of Illinois Urbana-Champaign. Ankyra is developing a novel anchored...